ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,136.99
0.42%
Dow Jones
43,292.36
-0.01%
Gold vs US Dollar
2,634.08
0.60%
Brent Oil
72.875
-0.56%
Bitcoin
95,471.41
-3.86%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. K V Pharma CL A (KVA)

  7. K V Pharma CL A (KVA) News

K V Pharma CL A (KVA)

K V Pharma CL A
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:KVA
DateTimeSourceHeadlineSymbolCompany
18/06/201213:04Dow Jones NewsU.S. HOT STOCK FUTURES: HOT STOCKS to WATCHNYSE:KVAK V Pharma CL A
18/06/201211:08Dow Jones NewsU.S. HOT STOCK FUTURES: HOT STOCKS to WATCHNYSE:KVAK V Pharma CL A
17/11/201101:15Business WireGlancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
03/11/201101:40Business WireLaw Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
01/11/201101:30Business WireGlancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
28/10/201120:30Business WireFaruqi & Faruqi, LLP Announces Investigation of K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
24/10/201117:52Business WireThe Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
21/10/201100:47Business WireLaw Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
13/10/201113:02Business WireZeldes & Haeggquist, LLP Announces Investigation of K-V PharmaceuticalNYSE:KVAK V Pharma CL A
13/06/201112:00PR Newswire (US)K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference CallNYSE:KVAK V Pharma CL A
01/04/201119:08Dow Jones NewsUPDATE: K-V Pharma Slashes Price Of Preterm Labor Drug Amid OutcryNYSE:KVAK V Pharma CL A
01/04/201114:28Dow Jones NewsK-V Pharma Slashes Prices Of Preterm Labor Drug After FDA MoveNYSE:KVAK V Pharma CL A
31/03/201121:28Dow Jones NewsReligious Groups Urge Drug Makers To Ease Up On Price HikesNYSE:KVAK V Pharma CL A
30/03/201119:58Dow Jones NewsUPDATE: K-V Pharma Shares Drop On FDA Statement On Preterm Birth DrugNYSE:KVAK V Pharma CL A
30/03/201116:38Dow Jones NewsK-V Pharma Shares Drop On FDA Statement On Preterm Birth DrugNYSE:KVAK V Pharma CL A
01/03/201113:49PR Newswire (US)K-V Pharmaceutical Company Announces $200 Million Private Debt OfferingNYSE:KVAK V Pharma CL A
14/02/201115:36PR Newswire (US)KV Pharmaceutical Company Announces Delay In Conference Call and Provides Overview Of Conference Call CommentsNYSE:KVAK V Pharma CL A
14/02/201115:34PR Newswire (US)K-V Pharmaceutical Company Announces Reliance on the Financial Distress Exception to NYSE's Shareholder Approval Policy to IssueNYSE:KVAK V Pharma CL A
14/02/201114:48PR Newswire (US)K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common StockNYSE:KVAK V Pharma CL A
04/02/201113:40PR Newswire (US)K-V Pharmaceutical Company to Host Investor Conference Call on February 14, 2011NYSE:KVAK V Pharma CL A
12/01/201114:03PR Newswire (US)K-V Pharmaceutical Company Updates Status of New Drug Application for Gestiva™NYSE:KVAK V Pharma CL A
14/09/201014:29Dow Jones NewsK-V Pharmaceutical Enters Loan Agreement In Wake Of FDA ApprovalNYSE:KVAK V Pharma CL A
10/09/201013:53Dow Jones NewsK-V Pharma Soars On FDA Approval To Return Product To MarketNYSE:KVAK V Pharma CL A
25/02/201018:53PR Newswire (US)KV Pharmaceutical Reaches Agreement with U.S. Department of JusticeNYSE:KVAN^CURN
28/01/201022:04Business WireRobbins Umeda LLP Announces Investigation of KV Pharmaceutical CompanyNYSE:KVAK V Pharma CL A
20/01/201020:41Dow Jones NewsUPDATE: Watson Pharma Benefits From Toprol Market PresenceNYSE:KVAK V Pharma CL A
20/01/201019:11Dow Jones NewsWatson Pharma Continues To Benefit From Toprol Market PresenceNYSE:KVAK V Pharma CL A
11/01/201014:18PR Newswire (US)KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM)NYSE:KVA
07/01/201021:10PR Newswire (US)KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of DirectorNYSE:KVA
22/12/200922:34PR Newswire (US)KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010NYSE:KVA
 Showing the most relevant articles for your search:NYSE:KVA

Your Recent History

LSE
SYME
Supply@me Capital
LSE
DEC
Diversified Energy
LSE
MAST
Mast Energy Developments
LSE
ALBA
Alba Mineral Resources
LSE
BOO
Boohoo
LSE
VAST
Vast Resources
LSE
SRSP
Sirius Petroleum
LSE
SWG
Shearwater
LSE
BARC
Barclays
LSE
LLOY
Lloyds Banking
LSE
EDEN
Eden Research
LSE
GOLD
LSE
ANCR
Animalcare
LSE
JDW
Wetherspoon ( J.d.)
LSE
ULT
Ultrasis
LSE
PRM
Proteome Sciences
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads